PT  - JOURNAL ARTICLE
AU  - Ramin Nourinia
AU  - Shintaro Nakao
AU  - Souska Zandi
AU  - Sare Safi
AU  - Ali Hafezi-Moghadam
AU  - Hamid Ahmadieh
TI  - ROCK inhibitors for the treatment of ocular diseases
AID  - 10.1136/bjophthalmol-2017-310378
DP  - 2018 Jan 01
TA  - British Journal of Ophthalmology
PG  - 1--5
VI  - 102
IP  - 1
4099  - http://bjo.bmj.com/content/102/1/1.short
4100  - http://bjo.bmj.com/content/102/1/1.full
SO  - Br J Ophthalmol2018 Jan 01; 102
AB  - The Rho-kinase/ROCK (Rho-associated coiled-coil-containing protein kinase) pathway is involved in the pathogenesis of multiple ocular and systemic disorders. Recently, ROCK inhibitors have been suggested as novel treatments for various ocular diseases. Several in vitro, in vivo and clinical studies have demonstrated the safety and efficacy of ROCK inhibitors in the management of ocular disorders such as corneal epithelial and endothelial damage, glaucoma, retinal and choroidal neovascularisation, diabetic macular oedema and optic nerve disorders. In this review, these studies are explored with focus on the relevant clinical investigations.